Previously treated patients with advanced renal cell carcinoma (RCC) given nivolumab had improved survival at three years compared with those treated with everolimus, according to updated results of the CheckMate 025 trial.
This is the first time a programmed death ligand-1 inhibitor has shown survival data of this duration, according to a press release from Bristol-Myers Squibb describing the presentation of the results at the 2017 International Kidney Care Symposium.
During the open-label,